National Trends and Outcomes of Patients Bridged to Transplant With Continuous Flow Left Ventricular Assist Devices.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 08 12 2018
accepted: 03 01 2019
entrez: 14 4 2019
pubmed: 14 4 2019
medline: 14 6 2019
Statut: ppublish

Résumé

Continuous flow left ventricular assist devices (CF-LVAD) are widely used as a bridge to transplantation (BTT) among patients with advanced heart failure. The primary outcome of the current study was to study the incidence of waitlist mortality and morbidity of CF-LVAD patients bridged to heart transplantation in the current BTT era and to determine the factors that increased their risk of delisting. Patients who were bridged to heart transplant with a CF-LVAD between April 2008 and September 2015 were identified from the United Network for Organ Sharing heart transplant registry. They were then categorized based on the development of complications. Cox proportional hazards and Kaplan-Meier survival curves were used for time-to-event analysis for the primary outcome. Out of 7070 patients who were bridged to heart transplant, 2510 (36%) developed device-related complications. The primary outcome was present in 1631 of 7070 patients (23%). Independent predictors of primary outcome were age, ABO blood group, etiology of cardiomyopathy, and history of diabetes mellitus. Developing one device-related complication was associated with a hazard ratio (HR) of 2.59 of having the primary outcome. The HR increased to 3.45 when ≥2 of the defined complications occurred. In patients who developed the primary outcome, they most likely had a device infection (odds ratio 2.51). Findings from the current study add to the existing literature about the incidence of morbidity and mortality in the current BTT era. Development of one device-related complication increases the risk of death or delisting among patients on the heart transplant waitlist; however, this risk almost doubles when 2 or more complications occur.

Sections du résumé

BACKGROUND BACKGROUND
Continuous flow left ventricular assist devices (CF-LVAD) are widely used as a bridge to transplantation (BTT) among patients with advanced heart failure. The primary outcome of the current study was to study the incidence of waitlist mortality and morbidity of CF-LVAD patients bridged to heart transplantation in the current BTT era and to determine the factors that increased their risk of delisting.
METHODS METHODS
Patients who were bridged to heart transplant with a CF-LVAD between April 2008 and September 2015 were identified from the United Network for Organ Sharing heart transplant registry. They were then categorized based on the development of complications. Cox proportional hazards and Kaplan-Meier survival curves were used for time-to-event analysis for the primary outcome.
RESULTS RESULTS
Out of 7070 patients who were bridged to heart transplant, 2510 (36%) developed device-related complications. The primary outcome was present in 1631 of 7070 patients (23%). Independent predictors of primary outcome were age, ABO blood group, etiology of cardiomyopathy, and history of diabetes mellitus. Developing one device-related complication was associated with a hazard ratio (HR) of 2.59 of having the primary outcome. The HR increased to 3.45 when ≥2 of the defined complications occurred. In patients who developed the primary outcome, they most likely had a device infection (odds ratio 2.51).
CONCLUSION CONCLUSIONS
Findings from the current study add to the existing literature about the incidence of morbidity and mortality in the current BTT era. Development of one device-related complication increases the risk of death or delisting among patients on the heart transplant waitlist; however, this risk almost doubles when 2 or more complications occur.

Identifiants

pubmed: 30979475
pii: S0041-1345(18)31641-5
doi: 10.1016/j.transproceed.2019.01.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

852-858

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

S Fugar (S)

Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA. Electronic address: setrifugar@yahoo.com.

A K Okoh (AK)

Department of Cardiothoracic Surgery, RWJ Barnabas Health, Newark Beth Israel Medical Center, Newark, New Jersey.

D Eshun (D)

Department of Medicine, Meharry Medical College, Nashville, Tennessee, USA.

J Yirerong (J)

Department of Internal Medicine, Brown University Memorial Hospital of Rhode Island, Providence, Rhode Island.

L T Appiah (LT)

Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.

C Mbachi (C)

Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA.

T Legge (T)

Boston Consulting Group, Chicago, Illinois, USA.

M Camacho (M)

Department of Cardiothoracic Surgery, RWJ Barnabas Health, Newark Beth Israel Medical Center, Newark, New Jersey.

M J Russo (MJ)

Department of Cardiothoracic Surgery, RWJ Barnabas Health, Newark Beth Israel Medical Center, Newark, New Jersey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH